Hedge Fund Investments Point to a Revival of Some Corners of the VC Market

As RA Capital and firms focused on life sciences have become more active, others, like Tiger Global, are mostly sitting on the sidelines.


Illustration by II

The venture capital market appears to be coming back to life — at least when it comes to the life sciences and biopharma sectors.

This is evident from the activity among hedge fund firms that either have separate VC arms or include privates in their long-short and long-only portfolios.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.